Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in Vitro

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5749-5755

  Kutko, Martha C ^a,b   Glick, Richard D ^b,c   Butler, Lisa M ^a,d   Coffey, Dennis C ^a,b   Rifkind, Richard A ^a,e   Marks, Paul A ^a   Richon, Victoria M ^a,e   LaQuaglia, Michael P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; PYROXAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FLOW CYTOMETRY; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; WESTERN BLOTTING;

ACETYLATION; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; FLOW CYTOMETRY; HISTONE DEACETYLASES; HISTONES; HUMANS; KINETICS; RHABDOMYOSARCOMA;

EID: 0344198097     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ruymann, F. B., and Grovas, A. C. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Investig., 18: 223-241, 2000.
2. Crist, W., Gehan, E. A., Ragab, A. H., Dickman, P. S., Donaldson, S. S., Fryer, C., Hammond, D., Hays, D. M., Herrmann, J., and Heyn, R. The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol., 13: 610-630, 1995.
3. Neville, H. L., Andrassy, R. J., Lobe, T. E., Bagwell, C. E., Anderson, J. R., Womer, R. B., Crist, W. M., and Wiener, E. S. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J. Pediatr. Surg., 35: 317-321, 2000.
4. Raney, R. B., Anderson, J. R., Barr, F. G., Donaldson, S. S., Pappo, A. S., Qualman, S. J., Wiener, E. S., Maurer, H. M., and Crist, W. M. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. Am. J. Pediatr. Hematol. Oncol., 23: 215-220, 2001.
5. Grunstein, M., Histone acetylation in chromatin structure and transcription. Nature (Lond.), 389: 349-352, 1997.
6. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998.
7. Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., and Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem., 274: 34940-34947, 1999.
8. Wolffe, A. P., and Kurumizaka, H. The nucleosome: a powerful regulator of transcription. Prog. Nucleic Acid Res. Mol. Biol., 61: 379-422, 1998.
9. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 12: 599-606, 1998.
10. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
11. Candido, E. P. M., Reeves, R., and Davie, J. R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell, 14: 105-113, 1978.
12. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res., 241: 126-133, 1998.
13. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999.
14. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93: 5705-5708, 1996.
15. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and LaQuaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res., 59: 4392-4399, 1999.
16. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., and Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res., 60: 5165-5170, 2000.
17. Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C., Scher, H. I., Breslow, R., Richon, V. M., Rifkind, R. A., and Marks, P. A. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res., 7: 962-970, 2001.
18. Kelly, W. K., O'Connor, O. A., and Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs, 11: 1695-1713, 2002.
19. Kelly, W. K., Richon, V. M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J. H., Rifkind, R., Marks, P. A., and Scher, H. Phase 1 clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clin. Cancer Res., 9: 3578-3588, 2003.
20. 1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (Baltimore), 13: 1243-1253, 1999.
21. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M., and Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 18: 2461-2470, 1999.
22. Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L. M., Rifkind, R. A., Marks, P. A., Richon, V. M., and LaQuaglia, M. P. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol., 35: 577-581, 2000.
23. Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., and Laquaglia, M. P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res., 61: 3591-3594, 2001.
24. Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D., and Richon, V. M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res., 19: 4999-5005, 1999.
25. Desai, D., Das, A., Cohen, L., El-Bayoumy, K., and Amin, S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. 23(1A): 499-503, 2003.
26. Feinberg, A. P. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res., 59 (Suppl.): 1743s-1746s, 1999.
27. Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R., and Naeve, C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res., 53: 5108-5112, 1993.
28. Davis, R. J., D'Cruz, C. M., Lovell, M. A., Biegel, J. A., and Barr, F. G. Fusion of PAX7 to FHRK by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res., 54: 2869-2872, 1994.
29. Xiao, H., Hasegawa, T., and Isobe, K. Both Sp1 and Sp3 are responsible for p21/WAF1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem., 73: 291-302, 1999.
30. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. Histone deacetylase inhibitor selectively induces p21/WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA, 97: 10014-10019, 2000.
31. Sowa, Y., Orita, T., Hiranabe-Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., and Sakai, T. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann. N. Y. Acad. Sci., 886: 195-199, 1999.
32. Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N., Matsukawa, Y., Tokino, T., Yamagishi, H., Oka, T., Nomura, H., and Sakai, T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem., 272: 22199-22206, 1997.